Lawmakers Get Blunt About Pot Reforms They’ve Rolled Out

November 16, 2023

McGlinchey is pleased to announce that Perry Salzhauer, co-chair of the firm’s Cannabis Industry Group resident in Seattle, has been recognized as a 2023 Notable Leader in Cannabis by Green Market Report.

October 17, 2023

The marijuana industry touted the passage of the SAFER Banking Act by the Senate Banking Committee, by a notable bipartisan majority of 14-9, on Sept. 27 and was placed on the Senate legislative calendar under general orders the following day. A Senate floor vote is now pending.

September 7, 2023

Associate Daniel Shortt (Seattle) was quoted in "The Feds Consider Making Marijuana Less Regulated," in Essence from his article "From Schedule I to Schedule III: Potential Shift in Marijuana’s Legal Status" where he discusses the possible classification change of cannabis from a Schedule I to Schedule III classification.

September 18, 2023

According to a report from the Congressional Research Service (the Report), the DEA is likely to follow the Department of HHS and the FDA's recommendation to move marijuana from Schedule I to Schedule III under the Controlled Substances Act.

September 12, 2023

A difficult lesson was learned after marijuana was discovered in a suitcase at the airport: The government does not have to prove cannabis is marijuana to convict you of trafficking in marijuana.

In the Media

September 6, 2023

Associate Daniel Shortt (Seattle) was quoted in "Rescheduling Cannabis Probably Won't Change as Much as You Think," in Cultivated about the proposed classification change of cannabis from Schedule I to Schedule III.

In the Media

August 31, 2023

Associate Daniel Shortt (Seattle) was quoted in "Marijuana Classification Change Would Alter Tax Collections" in The Bond Buyer.

August 30, 2023

Major news broke on August 30, 2023, as the U.S. Department of Health and Human Services (HHS) announced that it would recommend moving marijuana from Schedule I to Schedule III, as first reported by Riley Griffin for Bloomberg.

August 25, 2023

McGlinchey Stafford is pleased to announce that Heidi Urness and Daniel Shortt, attorneys in the firm’s Seattle office, have been named to the Super Lawyers 2023 Washington Rising Stars List.

Alert

July 25, 2023

Marijuana is currently listed as a Schedule I substance in the Controlled Substances Act (CSA); this scheduling means the federal government concluded marijuana has no currently accepted medical use in any setting. In a prior post, we analyzed how the Department of Health and Human Services (HHS), along with the Department of Justice, can opt for descheduling or rescheduling marijuana under the CSA.

Alert

June 16, 2023

The federal government aims to finish its review of marijuana’s current legal status by the end of 2023, based on remarks from the head of the U.S. Department of Health of Human Services, Secretary Xavier Becerra.

May 16, 2023

McGlinchey is pleased to announce that three nationally recognized attorneys who specialize in complex litigation, transactional, and regulatory matters across the spectrum of cannabis businesses have joined McGlinchey in Seattle and Albany.